17,261 trials
Acute Leukemia · Myelodysplastic Syndromes · Myeloproliferative Neoplasm
Primary: Determine the Optimal Dose of VIC-1911 When Given in Combination With Standard Immunosuppressive Therapy in Adult Patients Undergoing Myeloablative Stem Cell…
Acute Ischemic Stroke
Primary: Analysis of the National Institutes of Health Stroke Scale (NIHSS) Total Score Area Under the Curve During the Treatment Period — 3.83; 3.13 units on a scale
Breast Cancer · Chest Wall Disease
Primary: Disease Control Rate (DCR) at 18 Weeks — 20; 17 percentage of participants
Myeloid Malignancies · Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants Who Experienced Graft Failure — 0 Participants
Prostate Cancer
Primary: Progression-free Survival — 10.5; 11.8 Months
Metastatic Melanoma · Skin Cancer
Primary: Percentage of Participants Who Have a Clinical Response to Treatment (Objective Tumor Regression) — 27.5; 27.1; 19.6; 37.5 Percentage of participants
Cervicogenic Upper Extremity Radiculopathy
Primary: Change in Pain Numerical Rating Scale (Averaged Over Past 24 Hours) — -3.38; -2.30 score on a scale — p=0.057
Celiac Disease · Coeliac Disease
Primary: Changes From Baseline in Villous Height to Crypt Depth (Vh:Cd) as Assessed by Esophagogastroduodenoscopy With Biopsy After 2-week Gluten Challenge (GC) — -0.85; -0.61…
Salivary Gland Cancer
Primary: Best Overall Response Rate — 2; 5; 17; 8 Participants
Schizophrenia · Schizoaffective Disorder
Primary: Primary Clinical Outcome PANSS Total Score (PANSSt) — 65.4; 55.6; 67.1; 49.8 score on a scale — p=0.28
Advanced Solid Tumor
Primary: Number of Participants With Adverse Events and Deaths — 2; 2; 3; 3 Participants
Uncontrolled Hypertension
Primary: Number of Participants With Serum Total Cortisol Level Before and After Adrenocorticotropic Hormone (ACTH) Stimulation Test — 0; 0; 26; 15 Participants
Hereditary Angioedema · Hereditary Angioedema Type I · Hereditary Angioedema Type II
Primary: Change of the 3-symptom Composite Visual Analogue Scale (VAS-3) Score From Pre-treatment to 4 Hours Post-treatment — -14.83; -13.10; -14.37; 1.92 Score on a scale — p=<…
Non-Hodgkin's Lymphoma · Plasma Cell Myeloma
Primary: Number of Days to Discharge — 11; 15 days — p=0.001
Corneal Edema · Corneal Endothelial Dysfunction
Primary: Percentage of Participants Achieving ≥15-letter Improvement in Best-corrected Visual Acuity (BCVA) at Month 6 - Imputed Data — 14.3; 44.4; 10.5; 36.8 Percentage of…